Jersey Shore Ready ...
Health Care: Drugs
Progenics Pharmaceuticals Inc. (PGNX: NASDAQ)
$4.15 0.09 | 2.22%
05/24/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 58.84M | 70.10M | 47.92M | 90.90M |
| Receivables | 6.94M | 1.52M | 2.28M | 7.52M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.69M | 919.00K | 1.80M | 1.47M |
| Total Current Assets | 67.47M | 72.54M | 52.00M | 101.39M |
| Property, Plant & Equipment, Gross | 15.67M | 26.10M | 30.06M | 27.91M |
| Accumulated Depreciation & Depletion | 12.27M | 22.06M | 24.18M | 21.35M |
| Property, Plant & Equipment, Net | 3.40M | 4.04M | 5.88M | 6.56M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 3.39M | 3.53M | 4.86M | 5.66M |
| Total Non-Current Assets | 8.84M | 7.57M | 10.74M | 12.22M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 76.31M | 80.11M | 62.74M | 113.61M |
| Accounts Payable | 229.00K | 309.00K | 658.00K | 1.85M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 115.00K | 115.00K | 1.29M | 170.00K |
| Total Current Liabilities | 8.66M | 6.65M | 9.80M | 6.01M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 1.08M | 1.66M | 1.64M | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 1.08M | 1.66M | 1.64M | 0.00 |
| Total Liabilities | 9.74M | 8.31M | 11.43M | 6.01M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 66.57M | 71.80M | 51.31M | 107.61M |
| Common Par | 61.00K | 44.00K | 43.00K | 42.00K |
| Additional Paid In Capital | 493.61M | 463.44M | 453.35M | 439.94M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -424.10M | -388.67M | -399.06M | -329.33M |
| Treasury Stock | -2.74M | -2.74M | -2.74M | -2.74M |
| Other Equity Adjustments | -260.00K | -268.00K | -292.00K | -307.00K |
| Total Capitalization | 66.57M | 71.80M | 51.31M | 107.61M |
| Total Equity | 66.57M | 71.80M | 51.31M | 107.61M |
| Total Liabilities & Stock Equity | 76.31M | 80.11M | 62.74M | 113.61M |
| Total Common Shares Outstanding | 46.57M | 33.85M | 33.13M | 31.94M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 200.00K | 200.00K | 200.00K | 200.00K |
| Basic Weighted Shares Outstanding | 34.75M | 33.38M | 32.59M | 31.22M |
| Diluted Weighted Shares Outstanding | 34.75M | 33.49M | 32.59M | 31.22M |
| Number of Employees | 76 | 105 | 159 | 204 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with PGNX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorDrugs Facing FDA Approval i...
- UserGFNN Stockdiagnostics 14
- ContributorStocks Rising On Unusual Vo...
- ProTudor Investment
- ContributorStocks At New 52-Week Highs...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks At New 52-Week Highs...
Latest PGNX Headlines from TheStreet
- Progenics Pharmaceuticals Added To The NASDAQ Biotechnology Index 05.17.13 | 05:05 pm
- Progenics Pharmaceuticals Announces First Quarter 2013 Financial Results 05.10.13 | 07:05 am
- Progenics Pharmaceuticals To Host Conference Call To Review First Quarter 2013 Financial Results On May 10 05.06.13 | 05:05 pm
- Short Interest Moves 19% Higher For PGNX 04.25.13 | 04:04 pm
- Progenics Pharmaceuticals To Present At Needham Healthcare Conference 04.24.13 | 05:04 pm
- 'Mad Money' Lightning Round: I Like Priceline 04.02.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Checking My List 04.01.13 | 07:04 pm
- Progenics Pharmaceuticals Announces Fourth Quarter And Year-End 2012 Financial Results 03.15.13 | 07:03 am
- Progenics Pharmaceuticals To Host Conference Call To Review Fourth Quarter Financial Results On March 15 03.08.13 | 03:03 pm
- 5 Stocks Under $10 Set to Soar 03.07.13 | 01:03 pm
Press Releases for PGNX
- MedImmune Announces Agreement With Progenics Pharmaceuticals To Develop Therapies Against Serious Bacterial Infections - PR Newswire 12.17.12 | 09:12 am
- Salix And Progenics Receive Complete Response Letter From FDA For RELISTOR® SNDA - Business Wire 07.27.12 | 07:07 pm
- Salix And Progenics Announce Positive Highly Statistically Significant Results Of Oral Methylnaltrexone For Phase 3 Trial In Chronic, Non-Cancer Pain Subjects With Opioid-Induced Constipation - Business Wire 12.20.11 | 07:12 am
- Progenics And Salix Announce FDA Acceptance Of SNDA Filing For RELISTOR® In Patients With Non-Cancer Pain - Business Wire 08.30.11 | 07:08 am
- Progenics Pharmaceuticals To Webcast Upcoming Presentations - Business Wire 04.04.11 | 08:04 am
- Progenics Pharmaceuticals Announces Fourth Quarter And Year-End 2010 Financial Results - Business Wire 03.15.11 | 08:03 am
- Progenics Pharmaceuticals Announces Changes In Executive Responsibilities - Business Wire 03.09.11 | 07:03 am
- Progenics Reports Positive Preliminary Data From Ongoing Phase 1 Clinical Study Of PSMA ADC - Business Wire 02.17.11 | 04:02 pm
- Salix Pharmaceuticals And Progenics Pharmaceuticals Announce Worldwide License Agreement For RELISTOR® - Business Wire 02.07.11 | 07:02 am
- Progenics Pharmaceuticals And Salix Pharmaceuticals Announce Worldwide License Agreement For RELISTOR® - Business Wire 02.07.11 | 07:02 am
Partner Headlines for PGNX
- Progenics Pharmaceuticals Earnings: Everything You Must Know Now - Wall St. Cheat Sheet 05.10.13 | 09:05 am
- 5 Healthcare Companies With Recent Insider Buying - Seeking Alpha 11.18.12 | 09:11 am
- 5 Stocks That Dropped the Most Since Gurus Bought Them - NASDAQ 09.13.12 | 07:09 pm
- Another Delay for Salix Candidate - Analyst Blog - NASDAQ 09.10.12 | 10:09 pm
- Another Delay for Salix Candidate - Analyst Blog - Zacks 09.10.12 | 06:09 pm
- Stock Futures Mixed; Salix, Progenics Tumble - Investor's Business Daily 07.30.12 | 09:07 am
- Positive Data on Theravance Drug - Analyst Blog - Zacks 07.11.12 | 06:07 pm
- The Zacks Analyst Blog Highlights: US Airways Group, United Continental Holdings, Delta Airlines, Salix Pharmaceuticals and Progenics Pharmaceuticals - Press Releases - Zacks 04.24.12 | 09:04 am
- What's It Going To Take To Get Salix Cheap? - Seeking Alpha 02.29.12 | 08:02 am
- Progenics Should Outperform The Market In The Short Term - Seeking Alpha 02.15.12 | 08:02 am
